Literature DB >> 29938709

A Case of Refractory Pulmonary Coccidioidomycosis Successfully Treated with Posaconazole Therapy.

R H Patel1, S Pandya2, S Nanjappa3, J N Greene4.   

Abstract

Coccidioidomycosis is an endemic fungal infection caused by the inhalation of the spores of Coccidioides species. Patients with underlying immunosuppressive illness can contract chronic or disseminated disease which requires prolonged systemic therapy. Pulmonary coccidioidomycosis remains as an illusory and abstruse disease, with increased prevalence that poses as a challenge for clinicians in developing an effective strategy for treatment. Here, we report successful treatment of a refractory case of chronic relapsing pulmonary coccidioidomycosis in a 50-year old woman with a thin-walled cavitary lung lesion who was ultimately treated with posaconazole.

Entities:  

Keywords:  Cavitary lesion; Fluconazole; Posaconazole; Pulmonary coccidioidomycosis

Year:  2017        PMID: 29938709      PMCID: PMC6010061          DOI: 10.26420/jfammed.2017.1130

Source DB:  PubMed          Journal:  J Fam Med


  18 in total

1.  Coccidioidal pulmonary cavitation.

Authors:  L HYDE
Journal:  Am J Med       Date:  1958-12       Impact factor: 4.965

Review 2.  Coccidioidomycosis.

Authors:  John N Galgiani; Neil M Ampel; Janis E Blair; Antonino Catanzaro; Royce H Johnson; David A Stevens; Paul L Williams
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

3.  The varied roentgen manifestations of primary coccidioidomycosis.

Authors:  W H Greendyke; D L Resnick; W C Harvey
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1970-07

4.  Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis.

Authors:  J E Lutz; K V Clemons; B H Aristizabal; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.

Authors:  J N Galgiani; A Catanzaro; G A Cloud; R H Johnson; P L Williams; L F Mirels; F Nassar; J E Lutz; D A Stevens; P K Sharkey; V R Singh; R A Larsen; K L Delgado; C Flanigan; M G Rinaldi
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

Review 6.  Pulmonary coccidioidomycosis.

Authors:  Irene M Spinello; Augustine Munoz; Royce H Johnson
Journal:  Semin Respir Crit Care Med       Date:  2008-04       Impact factor: 3.119

Review 7.  Amphotericin B and coccidioidomycosis.

Authors:  Royce H Johnson; Hans E Einstein
Journal:  Ann N Y Acad Sci       Date:  2007-05-18       Impact factor: 5.691

8.  Redefining the clinical spectrum of chronic pulmonary histoplasmosis: a retrospective case series of 46 patients.

Authors:  Cassie C Kennedy; Andrew H Limper
Journal:  Medicine (Baltimore)       Date:  2007-07       Impact factor: 1.889

9.  The diagnosis of coccidioidomycosis.

Authors:  Neil M Ampel
Journal:  F1000 Med Rep       Date:  2010-01-18

10.  Increase in reported coccidioidomycosis--United States, 1998-2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-29       Impact factor: 17.586

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.